NASDAQ:BEAM Beam Therapeutics Q2 2026 Earnings Report $24.12 +0.13 (+0.54%) Closing price 04:00 PM EasternExtended Trading$24.15 +0.03 (+0.12%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Beam Therapeutics EPS ResultsActual EPS-$1.18Consensus EPS -$1.11Beat/MissMissed by -$0.07One Year Ago EPS-$1.00Beam Therapeutics Revenue ResultsActual Revenue$0.49 millionExpected Revenue$16.37 millionBeat/MissMissed by -$15.88 millionYoY Revenue Growth-94.20%Beam Therapeutics Announcement DetailsQuarterQ2 2026Date8/4/2026TimeBefore Market OpensConference Call DateTuesday, August 4, 2026Conference Call Time7:00AM ETUpcoming EarningsBeam Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Beam Therapeutics Earnings HeadlinesThese 10 Stocks Are Squeeze Candidates Waiting to Happen2 hours ago | benzinga.comBeam Therapeutics (NASDAQ:BEAM) Cut to Strong Sell at Wall Street ZenSeptember 13 at 1:06 AM | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.September 14 at 1:00 AM | Awesomely (Ad)Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My ViewSeptember 11 at 7:14 PM | seekingalpha.comWedbush Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)September 11 at 9:12 AM | theglobeandmail.comWedbush Reiterates "Outperform" Rating for Beam Therapeutics (NASDAQ:BEAM)September 11 at 2:52 AM | americanbankingnews.comSee More Beam Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email. Email Address About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source. The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers. Beam’s work combines base-editing systems with delivery technologies intended to transport editors to specific cells or tissues. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam was co-founded by scientists including David R. Liu and J. Keith Joung. The company conducts research and clinical development aimed at serving patients internationally and has entered collaborations and partnerships to advance its gene-editing platform and therapeutic programs.View Beam Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Kings to Buy While They’re Still Beaten DownAnalysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed EarningsMarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundThe End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
